Published in Am Heart J on July 01, 1999
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med (1993) 5.19
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion. Radiology (1993) 3.07
Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest (1995) 2.95
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med (1992) 2.63
Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology (1990) 2.14
Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest (1996) 2.14
Clinical uses of low-molecular-weight heparins. Chest (1999) 2.05
Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol (1996) 2.01
Controversies surrounding long-term anticoagulation of very elderly patients in atrial fibrillation. Chest (1998) 1.81
Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA (1995) 1.78
Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet (1996) 1.78
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost (2014) 1.74
Anticoagulation in dilated cardiomyopathy. J Am Coll Cardiol (1998) 1.69
Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest (1994) 1.64
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med (1982) 1.56
Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation (2001) 1.46
Pulmonary embolism presenting as seizures. Chest (1997) 1.46
Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. Chest (1998) 1.45
Lung scan evaluation of thrombolytic therapy for pulmonary embolism. J Nucl Med (1995) 1.44
Pulse-spray thrombolysis: the "careful analysis". Radiology (1994) 1.42
Physical exercise and reduced risk of nonfatal myocardial infarction. Am J Epidemiol (1995) 1.37
An overview of contemporary etiologies of congestive heart failure. Am Heart J (1991) 1.36
Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J (1995) 1.30
Risk factors for pulmonary embolism. The Framingham Study. Am J Med (1983) 1.28
Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest (1997) 1.27
Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol (1997) 1.25
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med (1990) 1.25
Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation (1995) 1.24
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation (1992) 1.20
Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med (1982) 1.15
A free-floating approach to filters. Arch Intern Med (1997) 1.08
The perils of D-dimer in the medical intensive care unit. Crit Care Med (2000) 1.07
Acute pulmonary embolism treated with tissue plasminogen activator. Lancet (1986) 1.06
Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med (1984) 1.06
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest (1992) 1.01
Cancer and venous thromboembolism. Am Heart J (1996) 1.01
Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med (1997) 1.00
Comparison of delay times to hospital presentation for physicians and nonphysicians with acute myocardial infarction. Am J Cardiol (1992) 0.99
Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J (1994) 0.98
Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost (2014) 0.97
Acute pulmonary embolism treated with thrombolytic agents: current status of tPA and future implications for emergency medicine. Ann Emerg Med (1988) 0.96
Chronic venous insufficiency: mechanisms and management. Am Heart J (1996) 0.96
Clinically significant venous thromboembolism after gynecologic surgery. J Reprod Med (1999) 0.96
Recovery of regional right ventricular function after thrombolysis for pulmonary embolism. Am J Cardiol (1999) 0.96
Ovarian vein thrombosis. Am Heart J (1993) 0.95
Biochemical markers of compliance in the Physicians' Health Study. Am J Prev Med (1991) 0.95
The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J (1991) 0.92
Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J (1997) 0.92
Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. Am Heart J (1991) 0.91
Chest radiographs in acute pulmonary embolism. Results from the International Cooperative Pulmonary Embolism Registry. Chest (2000) 0.90
Inosine: a protective agent in an organ culture model of myocardial ischemia. Circ Res (1982) 0.89
Constrictive pericarditis: a case requiring pericardiectomy following Dressler's postmyocardial infarction syndrome. J Thorac Cardiovasc Surg (1981) 0.89
Fiberoptics: morbidity and cost. N Engl J Med (1973) 0.89
Cardiovascular effects of potential occupational hazards. J Am Coll Cardiol (1983) 0.89
Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost (2006) 0.88
Time trends in hospital mortality and diagnosis of pulmonary embolism. Am Heart J (1982) 0.87
Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol (1987) 0.86
Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol (1996) 0.86
Multi-screen electronic alerts to augment venous thromboembolism prophylaxis. Thromb Haemost (2009) 0.86
Rapidly progressing dyspnea associated with a mass in the right side of the heart. Chest (1995) 0.85
Effects of the fiberoptic laparoscope and colonoscope on morbidity and cost. Ann Surg (1974) 0.84
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation (1992) 0.84
Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol (1992) 0.84
Randomized clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta-analysis. Am Heart J (1988) 0.83
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest (1995) 0.83
Thrombolysis in pulmonary embolism: a large-scale clinical trial is overdue. Circulation (2001) 0.83
Prevention by nifedipine of cold pressor-induced decrease in left ventricular ejection fraction. J Am Coll Cardiol (1983) 0.83
Short-term response to thrombolytic therapy in deep venous thrombosis: predictive value of venographic appearance. Radiology (1992) 0.83
Rescue percutaneous coronary intervention immediately following coronary artery bypass grafting. Chest (2001) 0.82
Valvular heart disease (aortic regurgitation and mitral valve prolapse) among institutionalized adults with Down's syndrome. Am J Cardiol (1986) 0.82
Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis (1999) 0.82
Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in US male physicians. Circulation (1997) 0.82
Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J (1996) 0.81
Utility of leg ultrasonography in suspected symptomatic isolated calf deep venous thrombosis. Am J Med (1995) 0.81
Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy. Circulation (1991) 0.80
High frequency of mitral valve prolapse and aortic regurgitation among asymptomatic adults with Down's syndrome. JAMA (1987) 0.80
G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol (2001) 0.80
Contemporary use of laboratory tests to monitor safety and efficacy of thrombolytic therapy. Chest (1992) 0.80
Low sensitivity of plasma DNA in screening for pulmonary embolism. Am Rev Respir Dis (1982) 0.80
Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation (1997) 0.79
Measurement of infarct size using single photon emission computed tomography and technetium-99m pyrophosphate: a description of the method and comparison with patient prognosis. Am J Cardiol (1982) 0.79
Epidemiologic characteristics, management, and outcome of deep venous thrombosis in a tertiary-care hospital: the Brigham and Women's Hospital DVT registry. Am Heart J (1996) 0.79
Uses of low-molecular-weight heparin. Blood Rev (1995) 0.79
Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement. Vasc Med (2001) 0.79
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am Heart J (1997) 0.79
How to select patients with deep vein thrombosis for tPA therapy. Chest (1989) 0.78
Late venous thromboembolic disease after radical prostatectomy: effect of risk factors, warfarin and early discharge. J Urol (1997) 0.78
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy. Circulation (1987) 0.77
Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. Chest (1998) 0.77
Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey. The TIPE Investigators. Chest (1989) 0.77
A critical pathway to evaluate suspected deep vein thrombosis. Arch Intern Med (1995) 0.77
Pulmonary embolism death rates. Am Heart J (1988) 0.77